 |
 |
The more I learn about the pharmaceutical industry the more disillusioned I become. E.g. Within weeks of the exclusive manufacturing rights for Eldepryl (Selegeline) expiring, it is found via "research" to be useless. That after I took 2 pills daily for 12 years!!! I'm starting to feel like a Pawn... Maybe I'm playing to much Chess online ;-) Nic 56/14 On Wed, Feb 18, 2009 at 8:14 PM, rayilynlee <[log in to unmask]> wrote: > Nic: > > Turner was on the infamous Prentice adult stem cell "cure" list a couple > of years ago and his case cited by Senator Sam Brownback on the floor of the > US Senate as a success for adult stem cells when arguing against the Stem > Cell Enhancement Act of 2007. Altho I never got a response from him, J. > Wesley Smith and Steven Ertelt have modified their characterization of > Turner from "cure" to "successful treatment" after I tangled with them > on-line. > > Since I thought I was through with this, I can't recall source for DBS > information, it was supposedly done because the ASC treatment wasn't > approved by the FDA like DBS and Levesque said Turner was never turned on. > > Now, why would anyone go through the ordeal of DBS and not see how it > worked. Also, I don't think you can have 2 procedures in one study and have > it be considered valid. > > Ray > > Rayilyn Brown > Director AZNPF > Arizona Chapter National Parkinson Foundation > [log in to unmask] > > -------------------------------------------------- > From: "Nic Marais" <[log in to unmask]> > Sent: Wednesday, February 18, 2009 12:27 AM > To: <[log in to unmask]> > Subject: Re: Important: Autologous Neural Stem Cells to Treat Parkinson's > > > Thanks for clearing this up Ray. I had a mind full of questions after >> reading the related article. >> >> Regards, >> >> Nic 56/14 >> >> On Tue, Feb 17, 2009 at 11:30 PM, rayilynlee <[log in to unmask]> wrote: >> >> You should know that Dennis Turner, the sole trial subject, had this >>> treatment in 1999, with a DBS. When I called him on 3-24-06 he told me >>> his >>> PD had returned with a vengeance. There is no current communication from >>> Turner as to his present condition. >>> >>> The FDA never approved of Phase II and I can only guess that because it >>> was >>> done with DBS it is impossible to tell what accounted for his temporary >>> improvement. Patricia Payne of MA was touted by the Family Research >>> Council >>> and David Prentice as an ASC "success" because she was going to be in >>> Phase >>> II, but Phase II never happened. >>> >>> I suspect that nothing has changed since 2006 except for the peer review >>> and they are dragging this case out again to get FDA approval and $. >>> Also >>> the assaults against embryonic stem cell research have intensified as >>> Obama >>> gets ready to issue executive orders to overturn the Bush restrictions. >>> >>> I did not post this article because of these omissions. >>> >>> Ray >>> >>> Rayilyn Brown >>> Director AZNPF >>> Arizona Chapter National Parkinson Foundation >>> [log in to unmask] >>> >>> -------------------------------------------------- >>> From: "schild.m" <[log in to unmask]> >>> Sent: Tuesday, February 17, 2009 3:16 AM >>> To: <[log in to unmask]> >>> Subject: Autologous Neural Stem Cells to Treat Parkinson's >>> >>> Groundbreaking Paper Publishes Long Term Results of a Successful Phase I >>> >>>> Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's >>>> Disease >>>> >>>> Last update: 9:11 a.m. EST Feb. 16, 2009 >>>> LOS ANGELES, Feb 16, 2009 /PRNewswire via COMTEX/ -- Scientists >>>> announced >>>> today the publication of a landmark peer-reviewed paper in the February >>>> issue >>>> of the Bentham Open Stem Cell Journal which outlines the long term >>>> results >>>> of >>>> the world's first clinical trial using autologous neural stem cells for >>>> the >>>> treatment of Parkinson's disease. According to lead author, Michel F. >>>> Levesque, MD, FRCS(C), FACS, "We have documented the first successful >>>> adult >>>> neural stem cell transplantation to reverse the effects of Parkinson's >>>> disease and demonstrated the long term safety and therapeutic effects of >>>> this >>>> approach." Dr Levesque is a principal investigator for NeuroGeneration, >>>> a >>>> biotechnology company, and is affiliated with the UCLA School of >>>> Medicine >>>> and >>>> the Brain Research Institute. >>>> The researcher reports that the publication of the article, "Therapeutic >>>> Microinjection of Autologous Adult Human Neural Stem Cells and >>>> Differentiated >>>> Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome" in >>>> the >>>> Bentham Open Stem Cell Journal heralds an important moment in >>>> regenerative >>>> and personalized medicine. "Our paper describes how we were able to >>>> isolate >>>> patient-derived neural stem cells, multiply them in vitro and ultimately >>>> differentiate them to produce mature neurons before they are >>>> reintroduced >>>> into the brain's basal ganglia. This is performed without the patient >>>> requiring immunosuppressants. Of particular note are the striking >>>> results >>>> this study yielded -- for the five years following the procedure the >>>> patient's motor scales improved by over 80% for at least 36 months. A >>>> word >>>> of >>>> caution must be added however, since this is a single case study, a >>>> larger >>>> clinical trial is needed to replicate these findings," says Levesque. >>>> "We have been pioneering the use of neural stem cells for >>>> neurodegenerative >>>> disorders since 1998 and were the first research team to successfully >>>> use >>>> differentiated adult neural stem cells for the cellular restoration and >>>> treatment of Parkinson's disease. Our original methodology is based on >>>> the >>>> replication of several steps in human neurogenesis to regenerate >>>> millions >>>> of >>>> mature neurons characterized before transplantation. These steps are >>>> essential to establish safety, efficacy and to understand mechanisms of >>>> brain >>>> repair. The autologous approach mitigates the long term risks associated >>>> with >>>> allogenic transplants, including infection, inflammatory response, >>>> immune >>>> rejection, and poor biologic efficacy. In addition, we believe it was >>>> the >>>> combination of dopaminergic and GABA-ergic neurons that produced the >>>> long- >>>> lasting motor improvement. This suggests that in humans, Parkinson's >>>> disease >>>> is more than a chronic dopaminergic dysfunction and involves the >>>> GABA-ergic >>>> system with its glial environment. The relevance of this discovery >>>> cannot >>>> be >>>> understated because it questions the classical dopaminergic model of >>>> Parkinson's disease," says Levesque. >>>> Scientists at NeuroGeneration are planning a larger prospective clinical >>>> trial for Parkinson's disease. "It's our hope that this trial will >>>> result >>>> in >>>> the launch of a cost-effective and lasting therapies for the millions of >>>> patients suffering from debilitating neurodegenerative disorders," >>>> concludes >>>> Levesque. >>>> ABOUT NEUROGENERATION: >>>> NeuroGeneration, a biotechnology company, is engaged in the development >>>> of >>>> biological products for the repair of neurological disorders. The >>>> company >>>> has >>>> completed a Phase I clinical trial for Parkinson's disease using adult >>>> derived neural stem cells. It intends to start a Phase II study for the >>>> treatment of Parkinson's disease as soon as it received final approval >>>> from >>>> the FDA. It is also planning Phase I studies for multiple systems >>>> atrophy, >>>> atypical parkinsonism, stroke, spinal cord and brain injuries, and >>>> Alzheimer's disease. The company was founded in 1998 and is >>>> headquartered >>>> in >>>> Los Angeles, California. >>>> FOR MORE INFORMATION CONTACT: >>>> Heather Larrabee >>>> NeuroGeneration >>>> 310.659.3880 >>>> [log in to unmask] >>>> http://www.neurogeneration.com >>>> >>>> ---------------------------------------------------------------------- >>>> To sign-off Parkinsn send a message to: mailto: >>>> [log in to unmask] >>>> In the body of the message put: signoff parkinsn >>>> >>>> >>> ---------------------------------------------------------------------- >>> To sign-off Parkinsn send a message to: mailto: >>> [log in to unmask] >>> In the body of the message put: signoff parkinsn >>> >>> >> ---------------------------------------------------------------------- >> To sign-off Parkinsn send a message to: mailto: >> [log in to unmask] >> In the body of the message put: signoff parkinsn >> > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn